A biopharmaceutical company engaged in the acquisition, research and development of promising medical technologies.
The best Bull and Bear pitches based on recency and number of recommendations.
Strong revenue growth from Xtandi and recent label expansion mode well for this stock.
At a stock price of 47 times book value, an unprofitable business and 162 dollars of debt for every dollar of equity what could possibly go wrong?
Read the most recent pitches from players about MDVN.DL.
Find the members with the highest scoring picks in MDVN.DL.
See what the Wall Street professionals think, according to their public statements and filings.